Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Bought by Ethic Inc.

Ethic Inc. increased its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 19.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,022 shares of the medical equipment provider's stock after acquiring an additional 6,906 shares during the period. Intuitive Surgical comprises 0.4% of Ethic Inc.'s investment portfolio, making the stock its 28th biggest holding. Ethic Inc.'s holdings in Intuitive Surgical were worth $21,934,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in ISRG. Bennett Selby Investments LP grew its holdings in shares of Intuitive Surgical by 3.9% in the fourth quarter. Bennett Selby Investments LP now owns 449 shares of the medical equipment provider's stock worth $234,000 after purchasing an additional 17 shares during the last quarter. Onefund LLC grew its holdings in shares of Intuitive Surgical by 1.9% in the fourth quarter. Onefund LLC now owns 947 shares of the medical equipment provider's stock worth $494,000 after purchasing an additional 18 shares during the last quarter. LVW Advisors LLC grew its holdings in shares of Intuitive Surgical by 1.3% in the fourth quarter. LVW Advisors LLC now owns 1,448 shares of the medical equipment provider's stock worth $756,000 after purchasing an additional 19 shares during the last quarter. Wesbanco Bank Inc. grew its holdings in shares of Intuitive Surgical by 1.6% in the fourth quarter. Wesbanco Bank Inc. now owns 1,216 shares of the medical equipment provider's stock worth $635,000 after purchasing an additional 19 shares during the last quarter. Finally, Journey Strategic Wealth LLC grew its holdings in shares of Intuitive Surgical by 1.9% in the fourth quarter. Journey Strategic Wealth LLC now owns 1,039 shares of the medical equipment provider's stock worth $542,000 after purchasing an additional 19 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company's stock.

Insider Transactions at Intuitive Surgical

In other news, CFO Jamie Samath sold 188 shares of the firm's stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $566.94, for a total transaction of $106,584.72. Following the sale, the chief financial officer now owns 7,162 shares of the company's stock, valued at $4,060,424.28. This trade represents a 2.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jami K. Nachtsheim sold 2,400 shares of the firm's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $520.00, for a total transaction of $1,248,000.00. Following the sale, the director now directly owns 6,371 shares in the company, valued at $3,312,920. The trade was a 27.36% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,313 shares of company stock valued at $17,229,143 in the last 90 days. 0.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have issued reports on ISRG shares. Piper Sandler dropped their target price on shares of Intuitive Surgical from $670.00 to $575.00 and set an "overweight" rating on the stock in a report on Wednesday, April 23rd. Jefferies Financial Group increased their target price on shares of Intuitive Surgical from $475.00 to $575.00 in a report on Monday, January 27th. Wells Fargo & Company increased their target price on shares of Intuitive Surgical from $630.00 to $687.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. BTIG Research set a $560.00 target price on shares of Intuitive Surgical and gave the stock a "buy" rating in a report on Monday, April 14th. Finally, Truist Financial dropped their target price on shares of Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, Intuitive Surgical has an average rating of "Moderate Buy" and an average target price of $598.95.

Intuitive Surgical Stock Down 0.3%

Shares of Intuitive Surgical stock traded down $1.61 during midday trading on Friday, hitting $536.55. The company had a trading volume of 925,598 shares, compared to its average volume of 1,631,682. Intuitive Surgical, Inc. has a 12-month low of $379.67 and a 12-month high of $616.00. The stock has a market cap of $192.31 billion, a price-to-earnings ratio of 83.71, a PEG ratio of 5.85 and a beta of 1.70. The company has a fifty day simple moving average of $500.93 and a 200 day simple moving average of $535.03.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.71 by $0.10. Intuitive Surgical had a net margin of 27.81% and a return on equity of 14.55%. The company had revenue of $2.25 billion during the quarter, compared to analyst estimates of $2.19 billion. During the same period last year, the firm posted $1.50 EPS. As a group, analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.